Who are Crizanlizumab Injection's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Selg1, ADAKVEO.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/crizanlizumab-injection.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Crizanlizumab Injection — Competitive Intelligence Brief

Crizanlizumab Injection (Crizanlizumab Injection) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: P-selectin inhibitor monoclonal antibody. Area: Hematology/Oncology.

marketed P-selectin inhibitor monoclonal antibody P-selectin Hematology/Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Crizanlizumab Injection (Crizanlizumab Injection) — Matthew Neal MD. Crizanlizumab is a monoclonal antibody that binds to P-selectin on the surface of platelets and endothelial cells, blocking platelet-endothelial interactions and reducing vaso-occlusive crises in sickle cell disease.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Crizanlizumab Injection TARGET	Crizanlizumab Injection	Matthew Neal MD	marketed	P-selectin inhibitor monoclonal antibody	P-selectin
Selg1	CRIZANLIZUMAB	Novartis	marketed	Selectin Blocker [EPC]	P-selectin	2019-01-01
ADAKVEO	CRIZANLIZUMAB-TMCA	NOVARTIS PHARMS CORP	marketed	Selectin Blocker [EPC]	P-selectin

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (P-selectin inhibitor monoclonal antibody class)

Matthew Neal MD · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Crizanlizumab Injection — Competitive Intelligence Brief. https://druglandscape.com/ci/crizanlizumab-injection. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab